When AbbVie Biotechnology Ltd. was sued in 2019 by indirect purchasers of Humira it was accused of securing over 100 patents to keep other drug companies from competing with the prescription drug that’s used to treat chronic conditions like rheumatoid arthritis.
But the theory that a company could be held liable for amassing too many patents and essentially being too much of an innovator was one no court had supported before, said Diana Watral, who represented Abbvie in the dispute.
Watral and her team at Kirkland & Ellis LLP were able to get the case dismissed in June from the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.